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Abstract
Introduction: Urokinase-type plasminogen activator (u-PA) has been implicated in fibrinolysis, cell migration, latent
cytokine activation, cell activation, T-cell activation, and tissue remodeling, all of which are involved in the
development of rheumatoid arthritis. Previously, u-PA has been reported to play a protective role in monoarticular
arthritis models involving mBSA as the antigen, but a deleterious role in the systemic polyarticular collagen-
induced arthritis (CIA) model. The aim of the current study is to determine how u-PA might be acting in systemic
arthritis models.
Methods: The CIA model and bone marrow chimeras were used to determine the cellular source of u-PA required
for the arthritis development. Gene expression of inflammatory and destructive mediators was measured in joint
tissue by quantitiative PCR and protein levels by ELISA. The requirement for u-PA in the type II collagen mAb-
induced arthritis (CAIA) and K/BxN serum transfer arthritis models was determined using u-PA
-/- mice. Neutrophilia
was induced in the peritoneal cavity using either ovalbumin/anti-ovalbumin or the complement component C5a.
Results: u-PA from a bone marrow-derived cell was required for the full development of CIA. The disease in u-PA
-/-
mice reconstituted with bone marrrow from C57BL/6 mice was indistinguishable from that in C57BL/6 mice, in
terms of clincal score, histologic features, and protein and gene expression of key mediators. u-PA
-/- mice were
resistant to both CAIA and K/BxN serum transfer arthritis development. u-PA
-/- mice developed a reduced
neutrophilia and chemokine production in the peritoneal cavity following ovalbumin/anti-ovalbumin injection; in
contrast, the peritoneal neutrophilia in response to C5a was u-PA independent.
Conclusions: u-PA is required for the full development of systemic arthritis models involving immune complex
formation and deposition. The cellular source of u-PA required for CIA is bone marrow derived and likely to be of
myeloid origin. For immune complex-mediated peritonitis, and perhaps some other inflammatory responses, it is
suggested that the u-PA involvement may be upstream of C5a signaling.
Introduction
Urokinase-type plasminogen activator (u-PA) is a serine
protease that, along with tissue-type plasminogen activa-
tor (t-PA), cleaves plasminogen to form plasmin [1]. The
plasminogen activator (PA)/plasmin system has been
implicated in the following processes in both physiology
and pathology: fibrinolysis, cell migration, latent cytokine
activation, cell activation via u-PA receptor (u-PAR),
T-cell activation, and tissue remodeling (directly or indir-
ectly via matrix metalloprotease (MMP) activation)
(reviewed in [1,2]).
Rheumatoid arthritis is a chronic systemic inflamma-
tory disease of unknown etiology, characterized by
synovial hyerplasia, infiltration of inflammatory cells,
intra-articular fibrin deposition and erosion of cartilage
and bone. Enhanced u-PA and reduced t-PA activity in
the synovium have been associated with rheumatoid
arthritis severity [3]. Increased levels of u-PAR, and
the PA inhibitors PAI-1 and PAI-2, are also found in
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types present in arthritic joints can produce PAs and
their inhibitors in vitro, including in response to inflam-
matory cytokines [4-11]. We and other workers have
previously reported that u-PA plays a protective role in
the antigen-induced arthritis (AIA) model [12] and the
mBSA/IL-1 monoarticular arthritis model [13], with u-
PA gene-deficient (u-PA
-/-) mice developing more severe
disease associated with increased intra-articular fibrin
deposition. In the chronic systemic collagen-induced
arthritis (CIA) model, however, we [14] and other work-
ers [15] have found that u-PA was deleterious, with
u-PA
-/- mice developing very mild disease and little
fibrin deposition. In addition, the T-cell proliferative
response to type II collagen (CII) was reduced in
u-PA
-/- mice, although the antibody response to CII was
normal [14]. Information on why u-PA depletion has
differing outcomes in these various arthritis models is
lacking but is essential if u-PA targeting is to be consid-
ered as a therapeutic strategy in rheumatoid arthritis
and other inflammatory conditions.
In order to examine how u-PA might be acting in the
systemic arthritis models, the following parameters were
assessed: the cellular source of u-PA required for CIA
development; inflammatory and destructive mediator
expression in the joints of C57BL/6 mice and u-PA
-/-
mice following CIA development; the requirement for
u-PA in the development of the CII mAb-induced
arthritis model (CAIA) and the K/BxN serum transfer
model of arthritis, both of which do not require B cells
or T cells, at least for the initiation of disease [16-18];
and the requirement for u-PA in the development of
immune complex-mediated neutrophilia in the perito-
neal cavity. We show that u-PA produced by a bone
marrow-derived cell is important for the full develop-
ment of CIA; many inflammatory and destructive med-
iators are increased in the joints of C57BL/6 mice but
not of u-PA
-/- mice following CIA development; u-PA
-/-
mice are essentially resistant to both CAIA and the K/
BxN serum transfer model of arthritis; and immune
complex-mediated neutrophilia and chemokine produc-
tion in the peritoneal cavity is u-PA dependent, whereas
C5a-mediated neutrophilia is not, suggesting u-PA is
acting upstream of C5a signaling.
Materials and methods
Mice
The u-PA
-/- mice, provided by Dr P Carmeliet (Univer-
sity of Leuven, Belgium), were backcrossed onto the
C57BL/6 background for 11 generations. C57BL/6
CD45 congenic mice, expressing the Ly5.1 allotype,
were obtained from Walter and Eliza Hall Institute Ani-
mal Supplies (Parkville, Victoria, Australia). All strains
were bred in our onsite animal facility, fed standard
rodent chow and water ad libitum, and housed in saw-
dust-lined cages in groups of five. Mice of both sexes,
8 to 12 weeks of age, were used in all experiments. All
experiments were approved by The Royal Melbourne
Hospital Research Foundation Animal Ethics
Committee.
Bone marrow transplantation
The u-PA
-/- or C57BL/6 recipient mice received total
body irradiation (two exposures × 5.5 Gy, 3 hours
apart). Bone marrow cells were harvested from the
femurs and tibiae of C57BL/6 or u-PA
-/- donor mice
expressing the Ly5.1 allotype of CD45. Recipient mice
(expressing the Ly5.2 allotype of CD45) were injected
intravenously with 5 × 10
6 bone marrow cells. Effective
bone marrow reconstitution was determined by flow
cytometry analysis of peripheral blood leukocytes 6
weeks later using the different congenic CD45 allotypes
(Ly5.1 and Ly5.2). Six weeks after irradiation, 95 ± 1%
of circulating leukocytes expressed the phenotypic mar-
ker of the donor bone marrow.
Collagen-induced arthritis
Mice were immunized intradermally in the base of the
tail with 100 μg chick CII (Sigma, St Louis, MO, USA),
emulsified in an equal volume of complete Freund’s
adjuvant containing 5 mg/ml heat-killed Mycobacterium
tuberculosis ( H 3 7R a ;D i f c o ,D e t r o i t ,M I ,U S A ) .T h i s
procedure was repeated as a boost 21 days later, as pre-
viously published [14].
Animals were assessed for redness and swelling of
limbs and a clinical score was allocated for each limb
using an established scoring system with slight modifica-
tions [14] as follows: 0 = normal; 1 = slight swelling
and/or erythema; 2 = extensive swelling and/or
erythema; 3 = severe swelling; 4 = rigidity. Severity of
arthritis is expressed in terms of the mean clinical score
(range 0 to 16 per mouse).
Type II collagen mAb-induced arthritis model
The anti-CII mAb-producing hybridomas for M2139
and CIIC1 were a gift from Prof. R Holmdahl (Karo-
linska Institute, Stockholm, Sweden). The cocktail of
M2139 and CIIC1 mAbs was prepared by mixing equal
concentrations of each of the antibody, and mice were
then injected intravenously with 4.5 mg mAb cocktail
on days 0 and 1. On day 5, mice received intraperitone-
ally 50 μg lipopolysaccharide (Escherichia coli serotype
0127:B8; Sigma-Aldrich), 5 μg Pam-3-Cys (EMC Micro-
collections, Tübingen, Germany), or PBS. Mice were
scored daily, using the same scoring system as for the
CIA model.
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K / B x Nm i c ew e r eb r e da sd e s cribed previously [19].
Serum was collected up to 12 weeks of age and stored
at -80°C. Serum (50 μl in 150 μl PBS) was injected intra-
peritoneally on days 0 and 2. Mice were scored daily,
using the same scoring system as for the CIA model.
Immune complex-mediated neutrophilia
Fifty microliters of chicken egg albumin (ovalbumin, 20
mg/kg body weight; Sigma) was injected intravenously
followed by intraperitoneal injection of 1 ml rabbit poly-
clonal IgG rich in antibody to chicken egg albumin
(anti-ovalbumin, 800 μg/mouse; Sigma), as previously
described [20]. Cells were harvested 4 hours later by
lavage with 5 ml ice-cold, sterile PBS. Total and differ-
ential cell counts (Diff-Quik; Lab Aids, Narrabeen,
NSW, Australia) were performed on the peritoneal exu-
date cells [21,22].
In certain experiments, C5a (1.25 μg; HyCult Biotech-
nology, Uden, The Netherlands) was given intraperito-
neally alone or administered together with the
anti-ovalbumin, as above. In these experiments, cells
were harvested 2 hours later.
Histology
At termination following arthritis induction, the rear
limbs and ankles were removed, fixed, decalcified, and
paraffin embedded, as previously described [14]. Fron-
tal sections (5 μm) were stained with either H & E to
examine joint architecture or with safranin O, fast
green and hematoxylin for proteoglycan loss, and were
evaluated without knowledge of the experimental
groups, using the histologic assessment as published
[14]. Briefly, infiltration of cells, cartilage damage and
bone erosions were all scored separately from 0 (nor-
mal) to 3 (severe), and proteoglycan loss was scored
from 0 (normal) to 3 (complete loss of staining). These
scores were added to give an overall histologic score
out of 12.
Detection of fibrin(ogen) by immunohistochemistry
Fibrin(ogen) deposition was identified in rear limbs as
before [14]. Briefly, paraffin-embedded sections were
deparaffinized, incubated with 1% (w/v) BSA and 5% (w/v)
skim milk powder for 1 hour, and then stained with a goat
anti-mouse fibrinogen/fibrin antibody (Accurate Chemical
& Scientific, Westbury, NY, USA) overnight at 4°C. Endo-
genous peroxidase activity was blocked with 0.3% (v/v)
H2O2 (Sigma) in methanol. Following washing, sections
were incubated with a biotinylated donkey anti-goat IgG
(Jackson ImmunoResearch, West Grove, PA, USA),
followed by a streptavidin-peroxidase conjugate (BD
Pharmingen, San Diego, CA, USA). Peroxidase activity
was demonstrated by incubation with 3-amino-9-ethylcar-
bazole (Sigma). Sections were counterstained with
hematoxylin.
Preparation of joint tissue washouts
Following sacrifice, the tendons and synovium from the
ankle joints of the hind limbs were dissected free from
the surrounding tissue and washed in 200 μlD M E M ,
supplemented with HEPES (20 mM), L-glutamine
(2 mM), and penicillin (50 U/ml)/streptomycin
(50 μg/ml), and were incubated for 1 hour at room
temperature to allow the elution of cytokines [14].
Supernatants were then removed and stored at -20°C
until assayed.
Cytokine ELISAs
TNFa and IL-1b levels were measured in ankle joint tis-
sue washouts by ELISA (OptEIA ELISA kits; BD Phar-
mingen), as outlined previously [14]. TNFa and IL-1b
ELISAs were sensitive down to 5 and 3 pg/ml, respec-
tively. Keratinocyte-derived chemokine (KC) and macro-
phage inflammatory protein-2 (MIP-2) levels were
measured in the peritoneal exudate fluid by ELISA
(DuoSet; R&D Systems, Minneapolis, MN, USA),
according to the manufacturer’si n s t r u c t i o n s :K Ca n d
MIP-2 ELISAs were sensitive down to 2 pg/ml.
MMP-9 expression in joint tissue washouts
Zymography was used to assess protease expression in
joint tissue washouts [23]. Briefly, joint washouts from
mice with the same arthritic score were pooled and con-
centrated. SDS-PAGE mini-gels (10%) were prepared
with the incorporation of gelatin (2 mg/ml; Labchem,
Pittsburgh, PA, USA) before casting. The joint washouts
(20 μl) were run into gels at a constant voltage of 200 V
under nonreducing conditions. When the dye front
reached the bottom, gels were removed and washed
twice for 15 minutes in 2.5% Triton X-100 and incu-
bated at 37°C overnight in zymography buffer (50 mM
Tris-HCl (pH 7.5), 5 mM CaCl2,1m MZ n C l 2 and
0.01% NaN3). The gels were then stained for 45 minutes
with Coomassie Brilliant Blue R-250 (Sigma) and exten-
sively destained. Following destaining, zones of enzyme
activity appeared clear against the Coomassie Blue
background.
Quantitative PCR analysis of gene expression
Quantitative PCR was performed as before [24]. Briefly,
joints were crushed, RNA was extracted using the
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and
cDNA was prepared. Quantitative PCR was performed
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TNFa,I L - 1 b, IL-6, MCP-1, t-PA, u-PA, u-PAR, MMP-
3, MMP-9, MMP-13, ADAMTS-4 and ADAMTS-5
(Applied Biosystems, Foster City, CA, USA), and was
read on an ABI Prism 7900H sequence detection sys-
tem, followed by analysis using ABI Prism SDS 2.1 soft-
ware. The TATA-binding protein (GeneWorks,
Thebarton, SA, Australia) was used as the control gene.
The comparative threshold method for relative quantifi-
cation was used, and results are expressed as relative
gene expression for each target gene.
Statistical analysis
For clinical and histologic scores and cytokine levels, the
Mann-Whitney two-sample rank test was used to deter-
mine the level of significance between two experimental
groups. For peritonitis and gene expression studies, an
unpaired Student’s t test was used; values are expressed
as the mean ± standard error of the mean. P ≤ 0.05 was
considered statistically significant.
Results
Bone marrow cell-derived u-PA is required for full
induction of collagen-induced arthritis
Based on in vitro studies, several different cell types pre-
sent in arthritic joints have been proposed to be poten-
tial sources of u-PA [10]. To determine the cellular
source of u-PA important for the development of arthri-
tis, bone marrow chimera experiments were performed
followed by the induction of CIA.
u-PA production by bone marrow-derived cell(s) is sufficient
C57BL/6 mice developed CIA with an incidence of 80%
(eight out of 10 mice) and average maximum clinical
severity of 4.1 ± 1.2. C57BL/6 sham chimeras (C57 ®
C57) developed disease of a similar incidence (92%, 11
out of 12 mice) and severity (Figure 1a), with an average
clinical severity of 4.4 ± 1.4, indicating that bone mar-
row transplantation per se did not affect the disease
development. u-PA
-/- mice developed mild CIA (Figure
1a), with a cumulative incidence of 75% (six out of eight
mice) and mean severity of 1.5 ± 0.6 (P < 0.05 compared
Figure 1 Collagen-induced arthritis development in C57BL/6 and u-PA
-/- chimeric mice. Urokinase-type plasminogen activator (u-PA)
production by bone marrow-derived cells is required for full expression of collagen-induced arthritis (CIA). (a) Severity (mean clinical score for all
mice ± standard error of the mean) for C57 (n = 10), C57 ® C57 (n = 12), C57 ® u-PA
-/- (n = 16) and u-PA
-/- (n = 8) mice. P < 0.05, C57 ® u-
PA
-/- vs. u-PA
-/- mice. (b) Severity for C57 (n = 10), u-PA
-/- ® C57 (n = 11), u-PA
-/- ®u-PA
-/- (n = 9), u-PA
-/- (n = 8) mice. P < 0.01, u-PA
-/- ® C57
vs. C57 mice.
Cook et al. Arthritis Research & Therapy 2010, 12:R37
http://arthritis-research.com/content/12/2/R37
Page 4 of 13with C57BL/6 mice), as previously reported [14]. Adop-
tively transferring bone marrow cells from C57BL/6
mice to irradiated u-PA
-/- mice (C57 ® u-PA
-/-)l e dt o
the development of CIA that was indistinguishable from
that induced in C57BL/6 mice (Figure 1a), with a cumu-
lative incidence of 69% (11 out of 16 mice) and a mean
maximum clinical score of 4.9 ± 1.2. The severity of
arthritis was significantly greater in these C57BL/6 ® u-
PA
-/- chimeras compared with u-PA
-/- mice (P <0 . 0 5 ) .
u-PA produced by a bone marrow-derived cell(s) is thus
sufficient for the full induction of CIA.
u-PA production by non-bone marrow-derived cell(s) is not
sufficient
To determine whether u-PA derived from a non-bone
marrow cell(s) could also restore disease in u-PA
-/-
mice, the reverse chimera experiment was performed
whereby bone marrow cells from u-PA
-/- mice were
transferred to irradiated C57BL/6 mice (u-PA
-/- ® C57).
u-PA
-/- sham chimeras, in which u-PA
-/- bone marrow
was transferred to irradiated u-PA
-/- mice (u-PA
-/- ® u-
PA), developed disease with a similar severity (Figure
1b) and incidence as u-PA
-/- mice; five out of nine
(56%) of the sham chimeras developed disease with a
low severity of 1.2 ± 0.4. The u-PA
-/- ® C57 chimeras
developed disease similar to u-PA
-/- mice (Figure 1b);
56% (seven out of 11) of the chimeras developed arthri-
tis with a mean maximum clinical score of 1.2 ± 0.4.
The severity of arthritis was significantly milder in these
u-PA
-/- ®C57 chimeras compared with C57 mice (P <
0.01). u-PA produced by a non-bone cell(s) is thus not
sufficient for full induction of CIA.
Histologic features of arthritis are similar in CIA-susceptible
chimeric mice as in C57BL/6 mice
By histology, the CIA in C57 ® C57 chimeras (Figure 2)
and C57BL/6 mice (data not shown) [14,25,26] were
indistinguishable in terms of cell infiltration, cartilage
destruction, proteoglycan depletion and bone erosions.
Likewise, the C57 ® u-PA
-/- chimeras, which were sus-
ceptible to arthritis, were similar in terms of the histolo-
gic features to the C57 ® C57 chimeras (Figure 2). In
contrast, u-PA
-/- ® C57 chimeras, which developed sig-
nificantly milder disease compared with C57BL/6 mice,
showed minimal histologic changes which were similar
to those observed in u-PA
-/- ® u-PA
-/- mice (Figure 2).
Inflammatory mediator production and gene expression in
joints are increased in CIA-susceptible C57BL/6 mice
compared with CIA-resistant u-PA
-/- mice
Our earlier study showed that TNF and IL-1b levels were
increased in joint washouts from CIA-susceptible wild-
type mice compared with CIA-resistant u-PA
-/- mice
[14]. TNF and IL-1b levels in joint washouts were signifi-
cantly higher in the arthritic C57 ® C57 and C57 ®
u-PA
-/- mice compared with u-PA
-/- ® u-PA
-/- and
u-PA
-/- ® C57 mice (Figure 3a). Likewise, gene
expression of TNF and IL-1b,a sw e l la so fI L - 6a n d
MCP-1, in joints was increased in arthritic C57BL/6 and
C57 ® u-PA
-/- chimeric mice compared with u-PA
-/-
mice following CIA development (P < 0.05 for each med-
iator, Figure 3b). Gene expression levels of joint t-PA and
u-PA were also increased in arthritic C57BL/6 mice com-
pared with u-PA
-/- mice (Figure 3c); however, mRNA
levels in joints from arthritic C57 ® u-PA
-/- chimeric
mice were intermediate between the increased levels in
arthritic C57BL/6 mice and levels in non-arthritic u-PA
-/-
mice (Figure 3c). For u-PA, this could be explained by
the fact that u-PA was only expressed in bone marrow-
derived cells in C57 ® u-PA
-/- chimeric mice. u-PAR
gene expression was increased in both arthritic C57BL/6
and C57 ® u-PA
-/- chimeric mice compared with u-
PA
-/- mice (P <0 . 0 1 ,C 5 7v s .u - P A
-/- mice; P < 0.05, C57
® u-PA
-/- vs. u-PA
-/- mice) (Figure 3c), despite the dif-
ference in u-PA expression.
MMP-3, MMP-9 and MMP-13 mRNA expression
levels were all increased in joints from arthritic C57BL/6
mice (P < 0.001, MMP-3; P < 0.01, MMP-9; P < 0.0001,
MMP-13) and C57 ® u-PA
-/- chimeric mice (P <
0.0001, MMP-3; P < 0.05, MMP-9; P < 0.05, MMP-13)
compared with those in u-PA
-/- mice (Figure 4a). By
zymography, MMP-9 activity was increased in joint
washouts from arthritic C57BL/6 mice with increasing
arthritis severity (Figure 4b). This activity in joint wash-
outs from u-PA
-/- mice was similar to that in C57BL/6
mice with no arthritis, in line with these mice having no
to very mild disease (Figure 4b). ADAMTS-4 mRNA
expression levels, but not those for ADAMTS-5, were
increased in both arthritic C57BL/6 mice (P < 0.001,
ADAMTS-4) and C57 ® u-PA
-/- chimeric mice (P <
0.05, ADAMTS-4) compared with those in u-PA
-/- mice
(Figure 4a).
The arthritis that develops in C57 ® u-PA
-/- chimeric
mice is thus indistinguishable from the arthritis seen in
C57BL/6 mice, both in terms of histologic features of
disease, as well as the protein and gene expression of
important inflammatory and destructive mediators.
u-PA
-/- mice are resistant to type II collagen mAb-induced
arthritis
We previously found [14] a reduced proliferative T-cell
response to CII stimulation in vitro in CII-primed u-
PA
-/- mice compared with CII-primed C57BL/6 mice
even though the antibody response to CII was similar
between the strains, suggesting normal immune com-
plex formation in u-PA
-/- mice following CIA induction.
In order to determine whether the reduced antigen-
specific T-cell response could explain the mild CIA
development in u-PA
-/- mice, the immune complex-
mediated CAIA model [27] was initiated in u-PA
-/- and
C57BL/6 mice. In contrast to CIA, this model bypasses
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Page 5 of 13Figure 2 Histologic features of arthritis are similar in arthritis-susceptible chimeric and C57BL/6 mice. (a) H & E staining.
Magnifications ×100. (b) Quantification of histologic features. C57 ® C57 (n = 6 limbs), C57 ® u-PA
-/- (n = 10 limbs), u-PA
-/- ® C57 (n = 6
limbs), u-PA
-/- ® u-PA
-/- (n = 6 limbs). Values expressed as mean ± standard error of the mean.
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Page 6 of 13Figure 3 Mediator production and gene expression in joints from mice immunized for collagen-induced arthritis. (a) TNF and IL-1b
levels in joint washouts following collagen-induced arthritis (CIA). TNF and IL-1b were measured by ELISA at sacrifice in washouts from ankle
joints of C57 ® C57 (n = 12), C57 ® u-PA
-/- (n = 16), u-PA
-/- ® C57 (n = 11) and u-PA
-/- ® u-PA
-/- (n = 9) mice. *P < 0.05, **P < 0.01, C57 ®
u-PA
-/- vs. u-PA
-/- ® u-PA
-/- mice; ***P < 0.05, ****P < 0.01, u-PA
-/- ® C57 vs. C57 ® C57 mice. (b) TNF, IL-1b, IL-6 and MCP-1 gene expression
levels in joints following CIA (n = 6 for each group). C57 or C57 ® u-PA
-/- vs. u-PA
-/- mice, P < 0.05 for each cytokine. (c) Tissue-type
plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA) and urokinase-type plasminogen activator receptor (u-PAR) gene
expression levels in joints following CIA (n = 6 for each group). C57 vs. u-PA
-/- mice, P < 0.05, t-PA and P < 0.01, u-PAR; C57 ® u-PA
-/- vs. u-PA
-/-
mice, P < 0.05, u-PAR. For (b) and (c), expression levels were normalized to an endogenous control (TATA-binding protein (TBP)) and calibrated
relative to expression in C57BL/6 mice. For all, values expressed as mean level ± standard error of the mean.
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requires LPS as a secondary stimulus to increase disease
severity [16]. The TLR2 ligand, Pam-3-Cys, was used as
a secondary stimulus, in place of LPS, as it gave more
severe arthritis in C57BL/6 mice (average maximum
clinical score 5. 3 ± 1.9 vs. 2.1 ± 1.3, Pam-3-Cys vs. LPS,
P < 0.05).
u-PA
-/- mice were resistant to CAIA compared with
C57BL/6 mice: 43% (three out of seven) of u-PA
-/- mice
developed arthritis with an average maximum clinical
score of 0.6 ± 0.2, compared with 80% (eight out of 10)
of C57BL/6 mice with an average maximum clinical
score of 5.3 ± 1.9 (P < 0.05). In fact, the three u-PA
-/-
mice developed very mild arthritis, each with a maxi-
mum score of only 1.
u-PA
-/- mice are resistant to K/BxN serum transfer arthritis
Another immune complex-driven arthritis model is the
K/BxN serum transfer model, in which serum from K/
BxN mice, which develop spontaneous arthritis, is able
to transfer the disease to naïve mice [19]. The arthritis
that develops is more severe than the CAIA model and
does not require an additional stimulus. C57BL/6 mice
developed rapid and severe arthritis following serum
transfer, whereas u-PA
-/- mice were essentially resistant
(Figure 5b): 60% (three out of five) of u-PA
-/- mice
developed arthritis with an average maximum clinical
score of 1.2 ± 0.5, compared with 100% (seven out of
seven) of C57BL/6 mice with an average maximum clin-
ical score of 11.1 ± 1.3 (P < 0.005). Once again the
three u-PA
-/- mice developed very mild arthritis, with a
maximum score of only 2.
By histology, C57BL/6 mice show massive cellular
infiltration, cartilage damage, proteoglycan loss, bone
erosion and fibrin(ogen) staining following K/BxN
serum transfer (Figure 5c, d). The joints from u-PA
-/-
mice, on the other hand, look relatively normal, with
minimal changes in these parameters (Figure 5c, d).
Figure 4 Matrix metalloprotease and aggrecanase gene expression and MMP-9 activity in mice immunized for collagen-induced
arthritis. (a) Matrix metalloprotease (MMP)-3, MMP-9, MMP-13, ADAMTS-4 and ADAMTS-5 gene expression levels in joints following collagen-
induced arthritis (CIA) (n = 6 for each group). C57 ® u-PA
-/- mice, P < 0.01, MMP-9; P < 0.001, MMP-3, ADAMTS-4; and P < 0.0001, MMP-13.
C57 ® u-PA
-/- vs. u-PA
-/- mice, P < 0.05, MMP-9, MMP-13, and ADAMTS-4; P < 0.0001, MMP-3. Expression levels were normalized to an
endogenous control (TATA-binding protein (TBP)) and calibrated relative to expression in C57BL/6 mice. Values expressed as mean level ±
standard error of the mean. (b) MMP-9 levels in joint washouts, measured by zymography, from C57BL/6 and u-PA
-/- mice with no arthritis (-),
mild arthritis (+) or severe arthritis (+++). Joint washouts were pooled (n = 3).
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Page 8 of 13Figure 5 Urokinase-type plasminogen activator gene-deficient mice are resistant to T-cell-independent arthritis models. (a) Type II
collagen mAb-induced arthritis (CAIA) using Pam-3-Cys as a boost. C57 (n = 10), u-PA
-/- (n = 7) mice. P < 0.05, u-PA
-/- vs. C57 mice. (b) K/BxN
serum transfer model. C57 (n = 7), u-PA
-/- (n = 5) mice. P < 0.0001, u-PA
-/- vs. C57 mice. (c) Histologic pictures of representative joints from
C57BL/6 and u-PA
-/- mice with K/BxN serum transfer arthritis. H & E, Safranin O fast green and fibrin(ogen) staining is shown. (d) Quantification
of histologic features. P < 0.05, u-PA
-/- vs. C57 mice for each histologic feature. Values expressed as mean ± standard error of the mean.
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Page 9 of 13u-PA is important for the development of immune
complex-mediated peritonitis
As already mentioned, the CIA model, the CAIA model
and the K/BxN serum transfer arthritis model all involve
immune complex formation and deposition in joints,
and, as shown above, all depend on the presence of u-
PA for disease progression. From the literature there is
a report showing a requirement for u-PA in immune
complex-driven lung inflammation [28]. In order to
explore further the proposed involvement of u-PA in
immune complex-dependent inflammation we required
am o d e lw h e r ew ec o u l da s s e s su - P Ad e p e n d e n c ef o l -
lowing direct application of an immune complex. As the
immune-complex arthritis model is induced using an
intra-articular injection [29], we decided against this as
such an injection leads to more severe arthritis in u-
PA
-/- mice [12,13], possibly due to the trauma involved.
For this reason, and also because the peritoneal cavity is
a convenient site for the isolation and quantification of
both extravasated inflammatory cells and also of inflam-
matory mediators, we used the immune complex-
mediated peritonitis model [20].
We have previously shown that u-PA was not required
for the development of murine peritonitis, as measured
by neutrophil and macrophage infiltration, using either
the nonspecific irritant, thioglycolate, as a stimulus, or
an antigen (methylated BSA)-specific stimulus [30]. The
lack of effect of u-PA deficiency with these stimuli
therefore gave us the opportunity to once again see
whether there is a particular association between
immune complexes and u-PA.
In u-PA
-/- mice there were significantly fewer neutro-
phils present in their peritoneal cavity compared with
C57BL/6 mice 4 hours post initiation of immune com-
plex-mediated neutrophilia (P < 0.01) (Figure 6a). The
levels of the chemokines, KC and MIP-2, shown pre-
viously to be produced following immune complex-
induced neutrophilia in the peritoneal cavity [20], were
measured. KC (P < 0.01) and MIP-2 (P < 0.01) (Figure
6b) levels were lower in the peritoneal exudate fluid of
u-PA
-/- mice compared with the levels in C57BL/6 mice.
This suggests that u-PA is involved in the initiation of
immune complex-mediated inflammatory response in
the peritoneal cavity leading to the production of che-
mokines and recruitment of neutrophils.
There is evidence that immune complexes induce the
bioactive complement component, C5a anaphylatoxin,
which, in turn, interacts with the C5aR, thus reducing
the threshold for Fcg-receptor activation and leading to
the recruitment of neutrophils into the peritoneal cavity
[20,31]. Also, ablation of C5aR signaling abrogates neu-
trophil recruitment and production of KC and MIP-2
[20]. Therefore, in order to determine whether u-PA
might be required downstream of C5a signaling in acute
peritonitis, C5a itself was given intraperitoneally and the
inflammatory response was followed. A 2-hour time
point was chosen for measurement of the neutrophilia
based on published literature [32]. Following intraperito-
neal injection of C5a there was no significant difference
in the number of recoverable peritoneal exudate cells
between u-PA
-/- and C57BL/6 mice (Figure 6c). As a
control, once again, stimulation with the immune com-
plex led to an increased number of recoverable
Figure 6 Urokinase-type plasminogen activator is important
for the development of immune complex-mediated, but not
C5a-mediated, neutrophilia. (a) Number of neutrophils in the
peritoneal exudate of C57BL/6 (n = 12) and u-PA
-/- (n = 12) mice 4
hours post injection of ovalbumin (OVA) intravenously and anti-OVA
intraperitoneally. (b) Levels of KC and MIP-2 in peritoneal exudate
fluid of C57BL6 (n = 8) and u-PA
-/- mice (n = 8) 4 hours post OVA/
anti-OVA injection, as measured by ELISA. (c) Total cell number in
the peritoneal exudate 2 hours post intraperitoneal injection of C5a
or immune complex (n = 6 per group). Values expressed as mean ±
standard error of the mean. *P < 0.01, **P < 0.001, C57 vs. u-PA
-/-
mice.
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Page 10 of 13peritoneal exudate cells from C57BL/6 mice, with a sig-
nificantly reduced number of exudate cells recoverable
from u-PA
-/- mice 2 hours post challenge (P < 0.001;
Figure 6c). Injection of saline alone did not induce sig-
nificant numbers of neutrophils at this time point (data
not shown). Since, from the data above, C5a-triggered
neutrophilia in the peritoneal cavity does not require u-
PA, it suggests that the u-PA involvement in immune
complex-mediated neutrophilia may not be downstream
of C5a signaling.
Discussion
We and other workers have previously shown that u-
PA
-/- mice develop very mild CIA [14,15], whereas these
same mice develop more severe AIA [12] and methy-
lated BSA/IL-1 arthritis [13] compared with C57BL/6
mice. Both the AIA and mBSA/IL-1 models are induced
using an intra-articular injection resulting in monoarti-
cular arthritis in the injected joint. In these monoarticu-
lar models, the enhanced disease severity seen in u-PA
-/-
mice correlated with increased fibrin(ogen) deposition in
the joint [12,13]. The beneficial role of u-PA in these
monoarticular models is thus likely to be in fibrinolysis.
The deleterious role of u-PA is less clear in CIA, with a
possible effect on T-cell activation, cell migration and/or
tissue destruction [1,2]. Using several polyarticular
arthritis models, which all involve immune complexes
and C5 activation [33,34], we showed here that u-PA is
important for full disease expression.
Based on in vitro studies, several different cell types
present in arthritic joints have been proposed to be
potential sources of u-PA [10]. For CIA development, u-
PA derived from a bone marrow cell(s), but not from a
nonbone marrow-derived cell(s), was shown to be
required for the full development of disease. A number
of different bone marrow-derived cell types are required
for CIA development, but lymphocytes are not required
for the CAIA and K/BxN serum transfer models [35],
suggesting it could be the myeloid cells that are produ-
cing u-PA required for arthritis development. Of note,
the monocyte/macrophage was one cell type proposed
as a source of u-PA in arthritis [10]. Gene expression of
several major proinflammatory and destructive media-
tors were similar in the joints of CIA-susceptible chi-
meric mice and wild-type mice, but increased compared
with CIA-resistant u-PA
-/- mice. Activation of procolla-
genases is a key control point in cartilage collagen
breakdown, and it has been shown, at least in vitro,t h a t
the PA/plasmin system can activate MMPs [36].
It has previously been reported that u-PA was
required for T-cell proliferation and activation in vitro,
and that its absence led to a reduced T-helper type-1-
polarized profile of cytokines [37]. We found T cells
from CII-primed u-PA
-/- mice had a reduced
proliferative response to CII in vitro compared with
wild-type mice although the in vivo antibody response
to CII was no different in u-PA
-/- mice, suggesting nor-
mal immune complex formation [14]. Here we found u-
PA
-/- mice to also be resistant to the CAIA and K/BxN
serum transfer models, which are T-cell-independent
models, at least for disease induction [16], suggesting
the defect in the antigen-specific T-cell response is unli-
kely to be solely responsible for the resistance of u-PA
-/-
mice to CIA [14]. In these models, where u-PA is dele-
terious, its role may be in migration of leukocytes to the
joints. The u-PA/u-PAR system has been implicated in
migration/chemotaxis of inflammatory cells [38-43],
although when using either thioglycolate or mBSA as
the stimulus we found no difference in the inflammatory
cell influx into the peritoneal cavity of u-PA
-/- mice
compared with C57BL/6 mice [30], suggesting that u-
PA is not always required for cell migration into tissues.
Another possible role for u-PA may be in the develop-
ment of immune complex-mediated inflammation. The
CIA, CAIA and the K/BxN serum transfer models all
involve immune complex formation and deposition in
joints, and u-PA has been reported to be required in an
immune complex-induced lung inflammation model
[28]. Whilst immune complexes have been reported in
AIA [44], this model does not require B cells [45], and
thus, disease development is not dependent on immune
complex formation. Utilizing the peritoneal cavity once
again we showed here that u-PA does appear to be
required for immune complex-mediated neutrophilia.
Immune complexes have been shown to activate the
complement system leading to the generation of C5a in
this peritonitis model, which then initiates the inflam-
matory cascade - both through direct C5aR-mediated
effector functions on infiltrating and resident cells, and,
also indirectly, by shifting the balance between activating
(FcgRI and FcgRIII) and inhibitory (FcgRIIB) Fcg recep-
tors on resident cells toward an inflammatory phenotype
[20]; also, ablation of C5aR signaling abrogates neutro-
phil recruitment and production of KC and MIP-2 in
the same model [20]. By analogy, the proposed setting
of a threshold for Fcg-receptor activation in immune
complex-mediated disease by C5a [20] could be occur-
ring in the CIA, CAIA and K/BxN arthritis models,
which are all C5a dependent [33,34].
As regards possible u-PA involvement in immune
complex-induced lung inflammation [28], it was pro-
posed that u-PA/u-PAR activation was necessary for
C5aR signaling in alveolar macrophages, which, in turn,
modulated the functional balance of the Fcg receptors.
Also, the presence of u-PA was shown to increase C5a-
induced MIP-2 and TNFa production by the alveolar
macrophage MH-S cell line in vitro, and blockade of u-
PAR on the cell surface completely prevented u-PA-
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C5a-stimulated MH-S cells [28]. Based on these findings
it was suggested that u-PA/u-PAR activation is impor-
tant for effective C5a/C5aR signaling in this model, and
perhaps others. We found following direct C5a adminis-
tration, however, that u-PA is not required for neutro-
phil migration into the peritoneal cavity, suggesting that
u-PA may rather be important for the generation of
adequate C5a for activation/signaling downstream of
immune complex activation rather than for C5a signal-
ing itself in immune complex-driven peritonitis. In the
absence of u-PA, lower levels of the chemokines KC
and MIP-2 were noted in the immune complex-driven
peritonitis model; it is therefore possible that there is
reduced chemotaxis of neutrophils rather than there
being an intrinsic defect in the ability of the cells to
migrate per se.
Apart from signaling via its receptor, u-PA also
cleaves plasminogen to form plasmin [1], which can
activate complement [46]. Plasminogen
-/- mice have
been shown to be resistant to both CIA and CAIA [15].
The relative contribution of u-PA signaling via its recep-
tor and/or via the generation of plasmin in immune
complex-mediated inflammatory responses is currently
being examined as it may be model specific.
Conclusions
u-PA is required for the full development of arthritis
models involving immune complex formation and
deposition - namely, the CIA, CAIA and K/BxN serum
transfer models - as opposed to the monoarticular mod-
els - AIA and mBSA/IL-1. The cellular source of u-PA
required for arthritis development, at least for the CIA
model, is bone marrow derived and possibly of myeloid
origin. From studies utilizing the peritoneal cavity and
from the work of others in the lung [28], it appears that
u-PA is important in other immune complex-mediated
inflammatory reactions. As mentioned, any connection
to complement involvement and associated mechanisms
require further analysis. Given that a number of autoim-
mune diseases are immune complex mediated, u-PA
m a yp r o v eas u i t a b l et h e r a p e u t i ct a r g e tf o rs u c h
diseases.
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